# OnCo record nct03268382 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03268382/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03268382", "NCT03268382" ;
  schema:name "p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246"@en ;
  schema:description "A phase 2 trial of Eprenetapopt and Pegylated liposomal doxorubicin in Ovarian cancer, run by Aprea Therapeutics, completed."@en ;
  schema:url <https://onco.cc/trials/nct03268382/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03268382> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:drugs <https://onco.cc/drugs/eprenetapopt/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/> ;
  onco:companies <https://onco.cc/companies/aprea-therapeutics/> .